Actively Recruiting
68Ga-NOTA-RM26 PET/CT in Glioma Patients
Led by Peking Union Medical College Hospital · Updated on 2024-05-14
30
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study was to investigate the value of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer, in the diagnosis of high WHO grade glioma and prediction the grade of glioma using positron-emission tomography/computed tomography (PET/CT).
CONDITIONS
Official Title
68Ga-NOTA-RM26 PET/CT in Glioma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Suspected or confirmed untreated glioma patients
- Signed written consent
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Known allergy against Pentixafor
- Any medical condition that may significantly interfere with study compliance according to the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese Academy of Medical Science & Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Z
Zhaohui Zhu
CONTACT
R
Rongxi Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here